Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Français (Suisse)
Italiano
Nederlands (Nederland)
Nederlands (België)
MARKETS
Equities
United States
North America
Europe
Asia
Middle East
More Equities
Indexes
S&P 500
DOW JONES
NASDAQ 100
EURO STOXX 50
NIKKEI 225
More Indexes
Currency / Forex
USD / EUR
USD / CAD
USD / MXN
USD / BRL
USD / INR
More Currencies
Commodities
GOLD
CRUDE OIL (WTI)
CRUDE OIL (BRENT)
SILVER
PLATINUM
More Commodities
Cryptocurrencies
BITCOIN
ETHEREUM
Trackers & ETF
Rankings and News
Advanced Search
NEWS
Latest News
Companies
Markets
Economy
Currency / Forex
Commodities
Interest Rates
Finance Pro.
Business Leaders
Cryptocurrencies
Cybersecurity
Economic Calendar
Listed companies
Analyst Reco.
Rumors
IPOs
Capital Markets Transactions
New Contracts
Profit Warnings
Appointments
Press Releases
Events
Security Transactions
Financial Calendar
Sector News
Energy
Basic Materials
Industrials
Consumer Cyclical
Consumer Non-Cyclical
Financials
Healthcare
Technology
Real Estate
Utilities
ANALYSIS
All Analysis
Must Read
Weekly market update
Stock Trading Strategies
STOCK PICKS
All Stock Picks
Subscribe
PORTFOLIOS
My Portfolio
Virtual Portfolios
MarketScreener Portfolios
USA Portfolio
European Portfolio
Asian Portfolio
WATCHLISTS
My Watchlists
Watchlists
My previous session
My most visited
Most popular
Investment Style
Yield stocks
Momentum stocks
Quality stocks
Growth stocks
Undervalued stocks
Trend-Following Stocks
Investment Themes
The Cannabis Industry
Strategic Metals
Place your bets
Boats
The Vegan Market
Water
RANKINGS
Top News
Most Read News
Hot News
Top Fundamentals
Top Capitalization
Top Yield
Top PER
Top Consensus
Top Fundamentals
Top ranking ESG
Top Technicals
Top RSI
Unusual volumes
Top Gaps
Top STIM
Breakouts
Trends
Top Movers
Top USA
Top Canada
Top U.K.
Top Germany
Top Europe
Top Asia
SCREENERS
Investment Themes
Financial Data
Water
Smart City
The SPAC
Biotechnology
The future of mobility
Technical Rankings
Oversold stocks
Overbought stocks
Close to resistance
Close to support
Accumulation Phases
Most volatile stocks
Fundamental Rankings
Top Investor Rating
Top Trading Rating
Top Consensus
Growth stocks
Yield stocks
Low valuations
Stock Screener Home
My Screeners
All my stocks
Watchlists
Virtual Portfolios
TOOLS
MarketScreener tools
Stock Screener
iPhone App
Expert tools
Stock Screener PRO
Portfolio Creator
Event Screener
Tools
Dynamic Chart
Financial Calendar
Economic Calendar
Sector Research
Currency Converter
ProRealTime Trading
OUR SERVICES
MarketScreener Portfolios
European Portfolio
USA Portfolio
Asian Portfolio
Our Stock Picks
Thematic Investment Lists
Stock Screener
Homepage
Equities
Japan
Japan Exchange
Takeda Pharmaceutical Company Limited
News
Analyst Reco.
4502
JP3463000004
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(4502)
Add to my list
Report
Delayed Japan Exchange -
02:00 2022-07-05 am EDT
3838.00
JPY
+0.68%
07/01
Takeda's Takhzyro Shows 94.8% Reduction in Hereditary Angioedema Attacks in Phase 3 Trial in Children
MT
06/30
TAKEDA PHARMACEUTICAL
: Phase 3 SPRING study data presented at EAACI
PU
06/30
Takeda's TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
BU
Summary
Quotes
Charts
News
Ratings
Calendar
Company
Financials
Consensus
Revisions
Summary
Most relevant
All News
Analyst Reco.
Other languages
Press Releases
Official Publications
Sector news
MarketScreener Strategies
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
2021
TAKEDA PHARMACEUTICAL
: Morgan Stanley Downgrades Takeda Pharmaceutical to Equal-weight Fr..
MT
2020
TAKEDA PHARMACEUTICAL
: Japan's Takeda says drug pipeline to lift sales to $48 billion in ..
RE
2018
Takeda clears key hurdle as investors back $59 billion Shire deal
RE
2018
Takeda investors back $59 billion Shire deal, but wary of debt load
RE
2018
Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favour
RE
2018
Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favor
RE
2018
Japan's Takeda clinches £45.3 billion Shire deal as pharma M&A rolls on
RE
2018
Overshadowed by Takeda bid, Shire reports solid start to year
RE
2018
Shire willing to back $64 billion Takeda bid, market signals doubts
RE
2018
Shire willing to back $64 billion Takeda bid, market signals doubts
RE
2018
Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
2018
Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
2018
Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
2018
Drugmaker Shire soars as Japan's Takeda considers bid
RE
2018
Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
RE
2017
BAYER
: Germany's Merck hires JP Morgan to sell consumer health
RE
2017
Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal
RE
2016
TAKEDA PHARMACEUTICAL
: Valeant rejected joint takeover bid from Takeda, TPG in spring - s..
RE
Analysis
Takeda, Nintendo among Japanese firms quietly celebrating weak yen
More Must read
Official Publications
05/11
Financial report
05/11
Press Release
05/11
Annual results
02/03
3rd quarter report
02/03
Press Release
02/03
3rd quarter results
More Official Publications
Upcoming event on TAKEDA PHARMACEUTICAL COMPANY LIMITED
07/28/22
Q1 2022 Earnings Release
Company calendar
Upcoming sector events
07/19/22
JOHNSON & JOHNSON
: Interim 2022 Earnings Release
07/21/22
ROCHE HOLDING AG
: Interim 2022 Earnings Release
07/28/22
PFIZER INC.
: Interim 2022 Earnings Release
07/29/22
ABBVIE INC.
: Interim 2022 Earnings Release (Projected)
More events
Sector
Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals
Slave